Table 1.
Characteristics of 129 subjects with leukemia
|
De novo
|
Treatment-related
|
Total (129) | |||||
|---|---|---|---|---|---|---|---|
| Group 1 11q23 (42) | Group 3 non-11q23 (57) | Total (99) | Group 2 11q23 (22) | Group 4 non-11q23 (8) | Total (30) | ||
| Mean age at Dx in yr, (SD), {n} | 2.2, (5.1), {42} | 7.7, (5.4), {49} | 11.2, (4.7), {22} | 14.1, (8.8), {8} | |||
| Male | 16 (38%) | 37 (65%) | 53 (53%) | 13 (59%) | 3 (38%) | 16 (53%) | 69 (53%) |
| Female | 26 (62%) | 19 (33%) | 45 (45%) | 9 (41%) | 5 (63%) | 14 (47%) | 59 (46%) |
| NA | 0 | 1 (2%) | 1 (1%) | 0 | 0 | 0 | 1 (1%) |
| White | 37 (88%) | 36 (63%) | 73 (74%) | 19 (86%) | 6 (75%) | 25 (83%) | 98 (76%) |
| Black | 3 (7%) | 9 (16%) | 12 (12%) | 0 | 0 | 0 | 12 (9%) |
| Hispanic | 2 (5%) | 3 (5%) | 5 (6%) | 3 (14%) | 1 (13%) | 4 (13%) | 9 (7%) |
| Asian | 0 | 2 (4%) | 2 (2%) | 0 | 0 | 0 | 1 (2%) |
| NA | 0 | 7 (12%) | 7 (7%) | 0 | 1 (13%) | 1 (3%) | 8 (6%) |
| ALL | 21 (50%) | 57 (100%) | 78 (79%) | 3 (14%) | 0 | 3 (10%) | 81 (63%) |
| AML | 18 (43%) | 0 | 18 (18%) | 16 (73%) | 4 (50%) | 20 (67%) | 38 (29%) |
| Biphenotypic | 3 (7%) | 0 | 3 (3%) | 1 (5%) | 0 | 1 (3%) | 4 (3%) |
| MDS | 0 | 0 | 0 | 2 (9%) | 4 (50%) | 6 (20%) | 6 (5%) |
| FAB L1 | 14 (33%) | 33 (58%) | 47 (47%) | 3 (13%) | 0 | 3 (10%) | 50 (39%) |
| FAB L2 | 3 (7%) | 9 (16%) | 12 (12%) | 0 | 0 | 0 | 12 (9%) |
| FAB M1 | 2 (5%) | 0 | 2 (2%) | 1 (5%) | 0 | 1 (3%) | 3 (2%) |
| FAB M2 | 2 (5%) | 0 | 2 (2%) | 2 (9%) | 0 | 2 (7%) | 4 (3%) |
| FAB M4 | 4 (9%) | 0 | 4 (4%) | 11 (50%) | 2 (25%) | 13 (43%) | 17 (13%) |
| FAB M5 | 10 (24%) | 0 | 10 (10%) | 2 (9%) | 1 (13%) | 3 (10%) | 13 (10%) |
| FAB M6 | 0 | 0 | 0 | 0 | 1 (13%) | 1 (3%) | 1 (1%) |
| FAB M7 | 0 | 0 | 0 | 1 (5%) | 0 | 1 (3%) | 1 (1%) |
| RAEB | 0 | 0 | 0 | 0 | 1 (13%) | 1 (3%) | 1 (1%) |
| RAEB-t | 0 | 0 | 0 | 0 | 1 (13%) | 1 (3%) | 1 (1%) |
| NA | 7 (17%) | 15 (26%) | 22 (22%) | 2 (9%) | 2 (25%) | 4 (13%) | 26 (20%) |
| Mean survival in mo, [SD], (range), {n} | 20.4, [19.0], (0.7–71.1), {39} | 37.9, [30.3], (6–125), {49} | 10.4, [10.5], (0.1–42), {20} | 6.6, [5.8], (0.3–15), {8} | |||
| Mean interval in mo, [SD], (range), {n} | Not applicable | Not applicable | 40.5, [31.4], (11–132), {22} | 55.3, [34.8], (14–113), {8} | |||
NA, not available; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; FAB, the French–American–British classification of morphology; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transition; {n}, number of subjects for whom information was available. Survival is from diagnosis of de novo or treatment-related leukemia. Interval is from diagnosis (Dx) of primary cancer to diagnosis of treatment-related leukemia.